Obesity drugs stocks
비만치료제
What are Obesity drugs stocks in Korea?
The Obesity drugs theme on jonbur groups 12 Korean stocks listed on KOSPI and KOSDAQ, worth ₩23T in total. On Oct 29, 2026 the group moved down 0.21% (weighted by market value); the largest members are Yuhan, Hanmi Pharm, SAM Chun Dang Pharm.
Key facts
- Stocks
- 12
- Total market value
- ₩23T
- Day's move
- −0.21%
- As of
- Oct 29, 2026
- Largest members
- Yuhan, Hanmi Pharm, SAM Chun Dang Pharm
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Yuhan | Oct 28Preliminary | ₩586B | +2.8% | ₩35B | +57.8% | −48.0% | 5.9%3.9% |
| Hanmi Pharm | Oct 27Preliminary | ₩377B | +4.2% | ₩38B | −31.3% | −71.2% | 10.0%15.2% |
| Dong-A ST | Oct 27Preliminary | ₩207B | −4.4% | ₩21B | +52.9% | +239.9% | 10.4%6.5% |
| HK inno.N | Expected around Oct 29 | ||||||
| IL Dong Pharmaceutical | Expected around Nov 6 | ||||||
| Daewoong Pharma | Expected around Nov 7 | ||||||
| G2GBIO | Expected around Nov 13 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| Peptron | Expected around Nov 14 | ||||||
| D&D Pharmatech | Expected around Nov 14 | ||||||
| Raphas | Expected around Nov 14 | ||||||
| Inventage Lab | Expected around Dec 1 | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 29, 2026- Above 20-day average
- 8.3%
- Above 60-day average
- 8.3%
- RSI above 70
- 0%
- RSI below 30
- 0%
- 52-week highs
- 0
- 52-week lows
- 0
Index gauge · Short term
Bearish
1 bullish, 1 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The obesity drugs theme covers 12 Korean stocks, and only 8.3% of them are trading above both their 20-day and 60-day averages. None of the members sit at a 52-week high or low, and none show an extreme RSI reading in either direction. The equal-weighted member index is bearish on both short- and medium-term gauges, with an RSI of 41.7 and price below its cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
No notable credit, ELS or macro events for these companies in the last 30 days.
Creators talking about this
Obesity drugs
−1.21%비만치료제
The obesity drugs theme covers Korean companies involved in developing, manufacturing, or contract-producing medications for weight management, including GLP-1-based injectables and related peptide therapies. Korean investors group these firms together because many of them supply active ingredients, formulation technology, or contract manufacturing for global pharmaceutical developers, and because the category has drawn attention from the broader global shift toward incretin-based treatments. The theme is often discussed alongside diabetes treatments, since many obesity drugs share mechanisms and development pathways with them.
12 companies · 2 up · 1 flat · 9 down
- Traded value
- ₩160B
- Value vs 20-day average
- 0.83×
- Top gainer
- Hanmi Pharm +5.14%
- Largest company
- Yuhan ₩5.5T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Yuhan000100 · KOSPI | ₩74,700 | −3.36% | ₩24B | ₩5.5T | 6.83% |
Hanmi Pharm128940 · KOSPI | ₩388,500 | +5.14% | ₩63B | ₩5T | 9.61% |
Daewoong Pharma069620 · KOSPI | ₩101,500 | +1.60% | ₩1.7B | ₩1.2T | 10.30% |
Source: KRX statistical information